hypothyroidism and glp-1 Hashimoto's GLP-1: what thyroid patients need to know before starting Implications of GLP-1 Receptor Agonist

Curr Ther Res Clin Exp 2023

Asia-Pacific Is the Fastest-Growing Access Region Through 2035 The United States holds a 62.8% GLP-1 Weight Loss Drug Market revenue share in 2026 , driven by the highest commercial drug pricing environment globally

J Clin Invest (1992) 90(4):13237

The Microdose Program utilizes up to 0.6mg per week of GLP-1 and is designed for weight loss specifically

More recently, sodium-glucose cotransporter type 2 inhibitors have demonstrated to offer cardiovascular and renal protection, but the residual risk remains high and their antihyperglycemic efficacy is limited in moderate-severe CKD

Other concerning symptoms that necessitate medical consultation include: Severe abdominal distension or inability to pass gas/stool (possible ileus or bowel obstruction) Nausea that worsens rather than improves after 812 weeks Inability to maintain adequate nutrition or hydration Unintentional weight loss exceeding clinical targets New or worsening heartburn or reflux symptoms Visual changes (especially with rapid blood sugar improvement) Severe headache or altered mental status Signs of gallbladder disease (right upper quadrant pain, especially after eating) Hypoglycemia symptoms if taking insulin or sulfonylureas Patients should generally not discontinue GLP-1 medications without medical guidance, except in emergencies such as suspected pancreatitis or severe allergic reaction